Getty ImagesRelated
Emkay Global has given buy rating Camlin Fine Sciences with a target price of Rs 115. The share price moved up by 0.05 per cent from its previous close of Rs 94.45. The stock’s last traded price is Rs 94.50.
Camlin Fine Sciences Ltd., incorporated in the year 1993, is a Small Cap company (having a market cap of Rs 1164.04 Crore) operating in Chemicals sector.
Financials
For the quarter ended 30-06-2020, the company reported a Consolidated sales of Rs 305.74 Crore, up 4.40 % from last quarter Sales of Rs 292.87 Crore and up 17.54 % from last year same quarter Sales of Rs 260.12 Crore The Company reported net profit after tax of Rs 20.56 Crore in latest quarter.
Investment Rationale
The brokerage believes that the commencement of the Dahej plant will be a game-changer in the long run and would improve the margin profile going forward. Moreover, the consolidation of Mexico and China facility would strengthen CFIN’s profitability. It expects revenue/EBITDA/PBT to grow at 18%/27%/45% CAGR over FY20-23E. It reiterates Buy with a TP of Rs115 (15x Sept’22) and OW in EAP.
Promoter/FII Holdings
Promoters held 22.7 per cent stake in the company as of June 30, 2020, while FIIs held 1.2 per cent, DIIs 19 per cent and public and others 57.1 per cent.
Camlin Fine Sciences Ltd., incorporated in the year 1993, is a Small Cap company (having a market cap of Rs 1164.04 Crore) operating in Chemicals sector.
Financials
For the quarter ended 30-06-2020, the company reported a Consolidated sales of Rs 305.74 Crore, up 4.40 % from last quarter Sales of Rs 292.87 Crore and up 17.54 % from last year same quarter Sales of Rs 260.12 Crore The Company reported net profit after tax of Rs 20.56 Crore in latest quarter.
Investment Rationale
The brokerage believes that the commencement of the Dahej plant will be a game-changer in the long run and would improve the margin profile going forward. Moreover, the consolidation of Mexico and China facility would strengthen CFIN’s profitability. It expects revenue/EBITDA/PBT to grow at 18%/27%/45% CAGR over FY20-23E. It reiterates Buy with a TP of Rs115 (15x Sept’22) and OW in EAP.
Promoter/FII Holdings
Promoters held 22.7 per cent stake in the company as of June 30, 2020, while FIIs held 1.2 per cent, DIIs 19 per cent and public and others 57.1 per cent.